How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Fremanezumab for preventing migraine

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about fremanezumab

Marketing authorisation indication

Fremanezumab (Ajovy, Teva Pharmaceuticals) is indicated for 'prophylaxis of migraine in adults who have at least 4 migraine days per month'.

Dosage in the marketing authorisation

2 dosing options are available: 225 mg once a month or 675 mg every 3 months (quarterly). Fremanezumab is administered as a subcutaneous injection.

The treatment benefit should be assessed within 3 months after starting treatment. Any decision to continue treatment should be taken on an individual patient basis. Evaluating the need to continue treatment is recommended regularly afterwards.

Price

£450.00 per 225 mg injection (£1,350 per 675 mg) excluding VAT; British national formulary online, accessed October 2019.

Costs may vary in different settings because of negotiated procurement discounts.